Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis had a pro-forma enterprise value of approximately USD 220m and a cash balance exceeding USD 117m prior to payment of […]
Tags : Nadia Tarolli
VISCHER has advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I which has raised USD 43 million in a first closing and is domiciled in Luxemburg. VISCHER has supported, in particular, regarding the setting up of Forty51 Advisory, in Basel which renders advisory services to the Fund. As […]
VISCHER has advised EBL on the sale of its Telekom division to Sunrise. EBL has been active in the telecom business since 2000 and owns telecom networks in around 200 communities in Switzerland. At the same time, EBL has been successfully pursuing a strong expansion of its business with renewable energy, heat production and distribution […]
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The Novaremed’s innovative non-opioid drug is being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the […]
Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. In connection with […]
msg systems, an international IT consulting and system integration company based in Munich, has acquired Optravis, a provider of SaaS solutions in operational transfer pricing management based in Basel. The terms of the deal were not disclosed. Vischer advised Optravis and the sellers on Swiss law in this cross-border transaction. The Vischer team was led […]
Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per share. Morgan Stanley and UBS were acting as Joint Global Coordinators and Joint Bookrunners and Zürcher Kantonalbank as Joint […]
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment. Vischer advises Novaremed with a […]
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in exchange for Polyphor Shares was signed. Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange. EnBiotix is also acquiring inhaled murepavadin for an agreed value of USD 10 million […]
Vischer advised the sellers of Mestex AG on all legal issues related to the sale of their shares and stock options to the pharmaceutical company Grünenthal, a global operator in pain management and related diseases. With the acquisition, Grünenthal aims to grow in the global market for osteoarthritis drugs and further strengthen its pain treatment-focused […]
